# US 2019/0194760 A1 · Novel biomarkers

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0194760 A1
- Document ID: US20190194760A1
- Status: Published application
- Kind: A1
- Application number: 16/304,381
- Filed: 2017-05-24
- Published: 2019-06-27
- Earliest claimed: 2016-05-25
- Applicants: CureVac AG
- Inventors: Sven KOCH; Henoch HONG; Mariola FOTIN-MLECZEK
- Web page: https://patentgrep.com/patent/US20190194760A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/118: Prognosis of disease development
- C12Q 2600/158: Expression markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present invention relates to methods of diagnosing, monitoring of a subject or determining the prognosis of a subject. In particular, the invention relates to a method of determining the prognosis of a cancer patient comprising the steps (a) determining the expression level of at least one marker gene selected from the group consisting of the marker genes as described herein in a sample of the cancer patient to obtain a gene expression profile; (b) determining the prognosis of the cancer patient based on the gene expression profile obtained in step (a). In addition, the present invention refers to kits, diagnostic compositions devices and microarrays for determining at least one marker gene and uses thereof.

## Claims

### Claim 1

A method of determining the prognosis of a patient comprising the steps of
(a) determining the expression level of at least 30 marker genes selected from the group consisting of the marker genes set out in table 4 in a sample of the patient to obtain a gene expression profile;
(b) determining the prognosis of the patient based on the gene expression profile obtained in step (a).

### Claim 2 (depends on 1)

Method according to claim 1, wherein the patient is a cancer or tumor patient.

### Claim 3 (depends on 1)

Method according to claim 1, wherein at least 10 additional marker genes, preferably at least 20 additional marker genes, more preferably at least 70 additional marker genes are selected from table 1.

### Claim 4

Method according to any one of the preceding claims, wherein at least 10 additional marker genes, preferably at least 20 additional marker genes, more preferably at least 70 additional marker genes are selected from table 2.

### Claim 5

Method according to any one of the preceding claims, wherein at least 10 additional marker genes, preferably at least 20 additional marker genes are selected from table 3.

### Claim 6

Method according to any one of the preceding claims, wherein the expression level of at least one marker gene is measured before administration and/or after administration of at least one dose of a therapeutic agent.

### Claim 7 (depends on 6)

Method according to claim 6, wherein the gene expression profile of step (a) is obtained by determining the difference of the expression level of the at least one marker gene measured before administration of the therapeutic agent and after administration of at least one dose of the therapeutic agent.

### Claim 8 (depends on 6, 7)

Method according to claim 6 or 7, wherein the therapeutic agent is an immunostimulatory composition and/or a vaccine and/or an immunotherapeutic agent.

### Claim 9 (depends on 6, 7, 8)

Method according to any one of claims 6 to 8, wherein the immunostimulatory composition and/or vaccine comprises at least one antigen selected from the group consisting of MAGE-C1, MAGE-C2, NY-ESO-1, Survivin and 5T4 or fragments or variants thereof.

### Claim 10 (depends on 6, 7, 8, 9)

Method according to any one of claims 6 to 9, wherein the immunostimulatory composition and/or vaccine comprises the antigens MAGE-C1, MAGE-C2, NY-ESO-1, Survivin and 5T4 or fragments or variants thereof.

### Claim 11 (depends on 6, 7, 8, 9, 10)

Method according to claim 6 to 10, wherein the antigen(s) are present as peptides or proteins and/or are encoded by at least one nucleotide sequence.

### Claim 12 (depends on 6, 7, 8, 9, 10, 11)

Method according to any one of claims 6 to 11, wherein the antigen(s) are encoded by at least one mRNA molecule.

### Claim 13 (depends on 6, 7, 8, 9, 10, 11, 12)

Method according to any one of claims 6 to 12, wherein the cancer is selected from the group consisting of Acute Lymphoblastic Leukemia, Adult; Acute Lymphoblastic Leukemia, Childhood; Acute Myeloid Leukemia, Adult; Adrenocortical Carcinoma; Adrenocortical Carcinoma, Childhood; AIDS-Related Lymphoma; AIDS-Related Malignancies; Anal Cancer; Astrocytoma, Childhood Cerebellar; Astrocytoma, Childhood Cerebral; Bile Duct Cancer, Extrahepatic; Bladder Cancer; Bladder Cancer, Childhood; Bone Cancer, Osteosarcoma/Malignant Fibrous Histiocytoma; Brain Stem Glioma, Childhood; Brain Tumor, Adult; Brain Tumor, Brain Stem Glioma, Childhood; Brain Tumor, Cerebellar Astrocytoma, Childhood; Brain Tumor, Cerebral Astrocytoma/Malignant Glioma, Childhood; Brain Tumor, Ependymoma, Childhood; Brain Tumor, Medulloblastoma, Childhood; Brain Tumor, Supratentorial Primitive Neuroectodermal Tumors, Childhood; Brain Tumor, Visual Pathway and Hypothalamic Glioma, Childhood; Brain Tumor, Childhood (Other); Breast Cancer; Breast Cancer and Pregnancy; Breast Cancer, Childhood; Breast Cancer, Male; Bronchial Adenomas/Carcinoids, Childhood: Carcinoid Tumor, Childhood; Carcinoid Tumor, Gastrointestinal; Carcinoma, Adrenocortical; Carcinoma, Islet Cell; Carcinoma of Unknown Primary; Central Nervous System Lymphoma, Primary; Cerebellar Astrocytoma, Childhood; Cerebral Astrocytoma/Malignant Glioma, Childhood; Cervical Cancer; Childhood Cancers; Chronic Lymphocytic Leukemia; Chronic Myelogenous Leukemia; Chronic Myeloproliferative Disorders; Clear Cell Sarcoma of Tendon Sheaths; Colon Cancer; Colorectal Cancer, Childhood; Cutaneous T-Cell Lymphoma; Endometrial Cancer; Ependymoma, Childhood; Epithelial Cancer, Ovarian; Esophageal Cancer; Esophageal Cancer, Childhood; Ewing's Family of Tumors; Extracranial Germ Cell Tumor, Childhood; Extragonadal Germ Cell Tumor; Extrahepatic Bile Duct Cancer; Eye Cancer, Intraocular Melanoma; Eye Cancer, Retinoblastoma; Gallbladder Cancer; Gastric (Stomach) Cancer; Gastric (Stomach) Cancer, Childhood; Gastrointestinal Carcinoid Tumor; Germ Cell Tumor, Extracranial, Childhood; Germ Cell Tumor, Extragonadal; Germ Cell Tumor, Ovarian; Gestational Trophoblastic Tumor; Glioma. Childhood Brain Stem; Glioma. Childhood Visual Pathway and Hypothalamic; Hairy Cell Leukemia; Head and Neck Cancer; Hepatocellular (Liver) Cancer, Adult (Primary); Hepatocellular (Liver) Cancer, Childhood (Primary); Hodgkin's Lymphoma, Adult; Hodgkin's Lymphoma, Childhood; Hodgkin's Lymphoma During Pregnancy; Hypopharyngeal Cancer; Hypothalamic and Visual Pathway Glioma, Childhood; Intraocular Melanoma; Islet Cell Carcinoma (Endocrine Pancreas); Kaposi's Sarcoma; Kidney Cancer; Laryngeal Cancer; Laryngeal Cancer, Childhood; Leukemia, Acute Lymphoblastic, Adult; Leukemia, Acute Lymphoblastic, Childhood; Leukemia, Acute Myeloid, Adult; Leukemia, Acute Myeloid, Childhood; Leukemia, Chronic Lymphocytic; Leukemia, Chronic Myelogenous; Leukemia, Hairy Cell; Lip and Oral Cavity Cancer; Liver Cancer, Adult (Primary); Liver Cancer, Childhood (Primary); Lung Cancer, Non-Small Cell; Lung Cancer, Small Cell; Lymphoblastic Leukemia, Adult Acute; Lymphoblastic Leukemia, Childhood Acute; Lymphocytic Leukemia, Chronic; Lymphoma, AIDS-Related; Lymphoma, Central Nervous System (Primary); Lymphoma, Cutaneous T-Cell; Lymphoma, Hodgkin's, Adult; Lymphoma, Hodgkin's; Childhood; Lymphoma, Hodgkin's During Pregnancy; Lymphoma, Non-Hodgkin's, Adult; Lymphoma, Non-Hodgkin's, Childhood; Lymphoma, Non-Hodgkin's During Pregnancy; Lymphoma, Primary Central Nervous System; Macroglobulinemia, Waldenstrom's; Male Breast Cancer; Malignant Mesothelioma, Adult; Malignant Mesothelioma, Childhood; Malignant Thymoma; Medulloblastoma, Childhood; Melanoma; Melanoma, Intraocular; Merkel Cell Carcinoma; Mesothelioma, Malignant; Metastatic Squamous Neck Cancer with Occult Primary; Multiple Endocrine Neoplasia Syndrome, Childhood; Multiple Myeloma/Plasma Cell Neoplasm; Mycosis Fungoides; Myelodysplasia Syndromes; Myelogenous Leukemia, Chronic; Myeloid Leukemia, Childhood Acute; Myeloma, Multiple; Myeloproliferative Disorders, Chronic; Nasal Cavity and Paranasal Sinus Cancer; Nasopharyngeal Cancer; Nasopharyngeal Cancer, Childhood; Neuroblastoma; Neurofibroma; Non-Hodgkin's Lymphoma, Adult; Non-Hodgkin's Lymphoma, Childhood; Non-Hodgkin's Lymphoma During Pregnancy; Non-Small Cell Lung Cancer; Oral Cancer, Childhood; Oral Cavity and Lip Cancer; Oropharyngeal Cancer; Osteosarcoma/Malignant Fibrous Histiocytoma of Bone; Ovarian Cancer, Childhood; Ovarian Epithelial Cancer; Ovarian Germ Cell Tumor; Ovarian Low Malignant Potential Tumor; Pancreatic Cancer; Pancreatic Cancer, Childhood’, Pancreatic Cancer, Islet Cell; Paranasal Sinus and Nasal Cavity Cancer; Parathyroid Cancer; Penile Cancer; Pheochromocytoma; Pineal and Supratentorial Primitive Neuroectodermal Tumors, Childhood; Pituitary Tumor; Plasma Cell Neoplasm/Multiple Myeloma; Pleuropulmonary Blastoma; Pregnancy and Breast Cancer; Pregnancy and Hodgkin's Lymphoma; Pregnancy and Non-Hodgkin's Lymphoma; Primary Central Nervous System Lymphoma; Primary Liver Cancer, Adult; Primary Liver Cancer, Childhood; Prostate Cancer; Rectal Cancer; Renal Cell (Kidney) Cancer; Renal Cell Cancer, Childhood; Renal Pelvis and Ureter, Transitional Cell Cancer; Retinoblastoma; Rhabdomyosarcoma, Childhood; Salivary Gland Cancer; Salivary Gland’ Cancer, Childhood; Sarcoma, Ewing's Family of Tumors; Sarcoma, Kaposi's; Sarcoma (Osteosarcoma)/Malignant Fibrous Histiocytoma of Bone; Sarcoma, Rhabdomyosarcoma, Childhood; Sarcoma, Soft Tissue, Adult; Sarcoma, Soft Tissue, Childhood; Sezary Syndrome; Skin Cancer; Skin Cancer, Childhood; Skin Cancer (Melanoma); Skin Carcinoma, Merkel Cell; Small Cell Lung Cancer; Small Intestine Cancer; Soft Tissue Sarcoma, Adult; Soft Tissue Sarcoma, Childhood; Squamous Neck Cancer with Occult Primary, Metastatic; Stomach (Gastric) Cancer; Stomach (Gastric) Cancer, Childhood; Supratentorial Primitive Neuroectodermal Tumors, Childhood; T-Cell Lymphoma, Cutaneous; Testicular Cancer; Thymoma, Childhood; Thymoma, Malignant; Thyroid Cancer; Thyroid Cancer, Childhood; Transitional Cell Cancer of the Renal Pelvis and Ureter; Trophoblastic Tumor, Gestational; Unknown Primary Site, Cancer of, Childhood; Unusual Cancers of Childhood; Ureter and Renal Pelvis, Transitional Cell Cancer; Urethral Cancer; Uterine Sarcoma; Vaginal Cancer; Visual Pathway and Hypothalamic Glioma, Childhood; Vulvar Cancer; Waldenstrom's Macro globulinemia; and Wilms' Tumor.

### Claim 14 (depends on 13)

Method according to claim 13, wherein the cancer is lung cancer, preferably non-small cell lung cancer (NSCLC).

### Claim 15

Method according to any one of the preceding claims, wherein the sample of the patient comprises peripheral blood mono-nuclear cells (PBMCs).

### Claim 16

Method according to any one of the preceding claims, wherein in step (b) a hierarchical clustering algorithm is applied.

### Claim 17

Kit, diagnostic composition or device for the analysis of at least one marker gene set out in table 1 comprising at least one primer and/or probe selective for determining the expression level of at least one marker gene set out in table 1.

### Claim 18 (depends on 17)

Kit, diagnostic composition or device of claim 17, further comprising an enzyme for primer elongation, nucleotides and/or labeling agents.

### Claim 19

Microarray, comprising at least one probe selective for determining the expression level of at least one marker gene set out in table 1.

### Claim 20 (depends on 19)

Use of a microarray according to claim 19 for determining the prognosis of a cancer patient.

### Claim 21 (depends on 17, 18)

Use of a kit, diagnostic composition or device according to claim 17 or 18 for determining the prognosis of a cancer patient.

### Claim 22

A method of determining the prognosis of a patient comprising the steps of
(a) determining the expression level of at least one marker gene selected from the group consisting of the marker genes set out in table 11 in a sample of the patient to obtain a gene expression profile;
(b) determining the prognosis of the patient based on the gene expression profile obtained in step (a).

### Claim 23 (depends on 22)

Method according to claim 22, wherein the patient is a cancer or tumor patient.

### Claim 24 (depends on 22, 23)

Method according to claim 22 or 23, wherein the at least one marker genes is selected from the group consisting of marker genes set out in table 12.

### Claim 25 (depends on 24)

Method according to claim 24, wherein the at least one marker gene is selected from the group consisting of marker genes set out in table 13.

### Claim 26 (depends on 25)

Method according to claim 25, wherein the at least one marker gene is selected from group consisting of marker genes set out in table 14.

### Claim 27 (depends on 26)

Method according to claim 26, wherein the at least one marker gene is selected from group consisting of marker genes set out in table 15.

### Claim 28 (depends on 22)

Method according to claim 22, wherein at least 10 marker genes, preferably at least 30 marker genes, more preferably at least 50 marker genes, most preferably at least 100 marker genes are selected from table 11.

### Claim 29 (depends on 24)

Method according to claim 24, wherein at least 10 marker genes, preferably at least 30 marker genes, more preferably at least 50 marker genes, most preferably at least 100 marker genes are selected from table 12.

### Claim 30 (depends on 25)

Method according to claim 25, wherein at least 10 marker genes, preferably at least 30 marker genes, more preferably at least 50 marker genes are selected from table 13.

### Claim 31 (depends on 26)

Method according claim 26, wherein at least 10 marker genes, preferably at least 20 marker genes, more preferably at least 30 marker genes a selected from the group consisting of from table 14.

### Claim 32 (depends on 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

Method according to any one of claims 22 to 31, wherein the expression level of at least one marker gene is measured before administration and/or after administration of at least one dose of a therapeutic agent.

### Claim 33 (depends on 32)

Method according to claim 32, wherein the gene expression profile of step (a) is obtained by determining the difference of the expression level of the at least one marker gene measured before administration of the therapeutic agent and after administration of at least one dose of the therapeutic agent.

### Claim 34 (depends on 32, 33)

Method according to claim 32 or 33, wherein the therapeutic agent is an immunostimulatory composition and/or a vaccine and/or an immunotherapeutic agent.

### Claim 35 (depends on 32, 33, 34)

Method according to any one of claims 32 to 34, wherein the immunostimulatory composition and/or vaccine comprises at least one antigen selected from the group consisting of MAGE-C1, MAGE-C2, NY-ESO-1, Survivin, 5T4, PSA, PSMA, PSCA, STEAP, PAP and MUC1 or fragments or variants thereof.

### Claim 36 (depends on 32, 33, 34, 35)

Method according to any one of claims 32 to 35, wherein the immunostimulatory composition and/or vaccine comprises the antigens
(i) MAGE-C1, MAGE-C2, NY-ESO-1, Survivin and 5T4 or fragments or variants thereof; or
(ii) PSA, PSMA, PSCA, STEAP, PAP and MUC1 or fragments or variants thereof.

### Claim 37 (depends on 32, 33, 34, 35, 36)

Method according to claim 32 to 36, wherein the antigen(s) are present as peptides or proteins and/or are encoded by at least one nucleotide sequence.

### Claim 38 (depends on 32, 33, 34, 35, 36, 37)

Method according to any one of claims 32 to 37, wherein the antigen(s) are encoded by at least one mRNA molecule.

### Claim 39 (depends on 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)

Method according to any one of claims 22 to 38, wherein the cancer is selected from the group consisting of Acute Lymphoblastic Leukemia, Adult; Acute Lymphoblastic Leukemia, Childhood; Acute Myeloid Leukemia, Adult; Adrenocortical Carcinoma; Adrenocortical Carcinoma, Childhood; AIDS-Related Lymphoma; AIDS-Related Malignancies; Anal Cancer; Astrocytoma, Childhood Cerebellar; Astrocytoma, Childhood Cerebral; Bile Duct Cancer, Extrahepatic; Bladder Cancer; Bladder Cancer, Childhood; Bone Cancer, Osteosarcoma/Malignant Fibrous Histiocytoma; Brain Stem Glioma, Childhood; Brain Tumor, Adult; Brain Tumor, Brain Stem Glioma, Childhood; Brain Tumor, Cerebellar Astrocytoma, Childhood; Brain Tumor, Cerebral Astrocytoma/Malignant Glioma, Childhood; Brain Tumor, Ependymoma, Childhood; Brain Tumor, Medulloblastoma, Childhood; Brain Tumor, Supratentorial Primitive Neuroectodermal Tumors, Childhood; Brain Tumor, Visual Pathway and Hypothalamic Glioma, Childhood; Brain Tumor, Childhood (Other); Breast Cancer; Breast Cancer and Pregnancy; Breast Cancer, Childhood; Breast Cancer, Male; Bronchial Adenomas/Carcinoids, Childhood: Carcinoid Tumor, Childhood; Carcinoid Tumor, Gastrointestinal; Carcinoma, Adrenocortical; Carcinoma, Islet Cell; Carcinoma of Unknown Primary; Central Nervous System Lymphoma, Primary; Cerebellar Astrocytoma, Childhood; Cerebral Astrocytoma/Malignant Glioma, Childhood; Cervical Cancer; Childhood Cancers; Chronic Lymphocytic Leukemia; Chronic Myelogenous Leukemia; Chronic Myeloproliferative Disorders; Clear Cell Sarcoma of Tendon Sheaths; Colon Cancer; Colorectal Cancer, Childhood; Cutaneous T-Cell Lymphoma; Endometrial Cancer; Ependymoma, Childhood; Epithelial Cancer, Ovarian; Esophageal Cancer; Esophageal Cancer, Childhood; Ewing's Family of Tumors; Extracranial Germ Cell Tumor, Childhood; Extragonadal Germ Cell Tumor; Extrahepatic Bile Duct Cancer; Eye Cancer, Intraocular Melanoma; Eye Cancer, Retinoblastoma; Gallbladder Cancer; Gastric (Stomach) Cancer; Gastric (Stomach) Cancer, Childhood; Gastrointestinal Carcinoid Tumor; Germ Cell Tumor, Extracranial, Childhood; Germ Cell Tumor, Extragonadal; Germ Cell Tumor, Ovarian; Gestational Trophoblastic Tumor; Glioma. Childhood Brain Stem; Glioma. Childhood Visual Pathway and Hypothalamic; Hairy Cell Leukemia; Head and Neck Cancer; Hepatocellular (Liver) Cancer, Adult (Primary); Hepatocellular (Liver) Cancer, Childhood (Primary); Hodgkin's Lymphoma, Adult; Hodgkin's Lymphoma, Childhood; Hodgkin's Lymphoma During Pregnancy; Hypopharyngeal Cancer; Hypothalamic and Visual Pathway Glioma, Childhood; Intraocular Melanoma; Islet Cell Carcinoma (Endocrine Pancreas); Kaposi's Sarcoma; Kidney Cancer; Laryngeal Cancer; Laryngeal Cancer, Childhood; Leukemia, Acute Lymphoblastic, Adult; Leukemia, Acute Lymphoblastic, Childhood; Leukemia, Acute Myeloid, Adult; Leukemia, Acute Myeloid, Childhood; Leukemia, Chronic Lymphocytic; Leukemia, Chronic Myelogenous; Leukemia, Hairy Cell; Lip and Oral Cavity Cancer; Liver Cancer, Adult (Primary); Liver Cancer, Childhood (Primary); Lung Cancer, Non-Small Cell; Lung Cancer, Small Cell; Lymphoblastic Leukemia, Adult Acute; Lymphoblastic Leukemia, Childhood Acute; Lymphocytic Leukemia, Chronic; Lymphoma, AIDS-Related; Lymphoma, Central Nervous System (Primary); Lymphoma, Cutaneous T-Cell; Lymphoma, Hodgkin's, Adult; Lymphoma, Hodgkin's; Childhood; Lymphoma, Hodgkin's During Pregnancy; Lymphoma, Non-Hodgkin's, Adult; Lymphoma, Non-Hodgkin's, Childhood; Lymphoma, Non-Hodgkin's During Pregnancy; Lymphoma, Primary Central Nervous System; Macroglobulinemia, Waldenstrom's; Male Breast Cancer; Malignant Mesothelioma, Adult; Malignant Mesothelioma, Childhood; Malignant Thymoma; Medulloblastoma, Childhood; Melanoma; Melanoma, Intraocular; Merkel Cell Carcinoma; Mesothelioma, Malignant; Metastatic Squamous Neck Cancer with Occult Primary; Multiple Endocrine Neoplasia Syndrome, Childhood; Multiple Myeloma/Plasma Cell Neoplasm; Mycosis Fungoides; Myelodysplasia Syndromes; Myelogenous Leukemia, Chronic; Myeloid Leukemia, Childhood Acute; Myeloma, Multiple; Myeloproliferative Disorders, Chronic; Nasal Cavity and Paranasal Sinus Cancer; Nasopharyngeal Cancer; Nasopharyngeal Cancer, Childhood; Neuroblastoma; Neurofibroma; Non-Hodgkin's Lymphoma, Adult; Non-Hodgkin's Lymphoma, Childhood; Non-Hodgkin's Lymphoma During Pregnancy; Non-Small Cell Lung Cancer; Oral Cancer, Childhood; Oral Cavity and Lip Cancer; Oropharyngeal Cancer; Osteosarcoma/Malignant Fibrous Histiocytoma of Bone; Ovarian Cancer, Childhood; Ovarian Epithelial Cancer; Ovarian Germ Cell Tumor; Ovarian Low Malignant Potential Tumor; Pancreatic Cancer; Pancreatic Cancer, Childhood’, Pancreatic Cancer, Islet Cell; Paranasal Sinus and Nasal Cavity Cancer; Parathyroid Cancer; Penile Cancer; Pheochromocytoma; Pineal and Supratentorial Primitive Neuroectodermal Tumors, Childhood; Pituitary Tumor; Plasma Cell Neoplasm/Multiple Myeloma; Pleuropulmonary Blastoma; Pregnancy and Breast Cancer; Pregnancy and Hodgkin's Lymphoma; Pregnancy and Non-Hodgkin's Lymphoma; Primary Central Nervous System Lymphoma; Primary Liver Cancer, Adult; Primary Liver Cancer, Childhood; Prostate Cancer; Rectal Cancer; Renal Cell (Kidney) Cancer; Renal Cell Cancer, Childhood; Renal Pelvis and Ureter, Transitional Cell Cancer; Retinoblastoma; Rhabdomyosarcoma, Childhood; Salivary Gland Cancer; Salivary Gland’ Cancer, Childhood; Sarcoma, Ewing's Family of Tumors; Sarcoma, Kaposi's; Sarcoma (Osteosarcoma)/Malignant Fibrous Histiocytoma of Bone; Sarcoma, Rhabdomyosarcoma, Childhood; Sarcoma, Soft Tissue, Adult; Sarcoma, Soft Tissue, Childhood; Sezary Syndrome; Skin Cancer; Skin Cancer, Childhood; Skin Cancer (Melanoma); Skin Carcinoma, Merkel Cell; Small Cell Lung Cancer; Small Intestine Cancer; Soft Tissue Sarcoma, Adult; Soft Tissue Sarcoma, Childhood; Squamous Neck Cancer with Occult Primary, Metastatic; Stomach (Gastric) Cancer; Stomach (Gastric) Cancer, Childhood; Supratentorial Primitive Neuroectodermal Tumors, Childhood; T-Cell Lymphoma, Cutaneous; Testicular Cancer; Thymoma, Childhood; Thymoma, Malignant; Thyroid Cancer; Thyroid Cancer, Childhood; Transitional Cell Cancer of the Renal Pelvis and Ureter; Trophoblastic Tumor, Gestational; Unknown Primary Site, Cancer of, Childhood; Unusual Cancers of Childhood; Ureter and Renal Pelvis, Transitional Cell Cancer; Urethral Cancer; Uterine Sarcoma; Vaginal Cancer; Visual Pathway and Hypothalamic Glioma, Childhood; Vulvar Cancer; Waldenstrom's Macro globulinemia; and Wilms' Tumor.

### Claim 40 (depends on 39)

Method according to claim 39, wherein the cancer is lung cancer or prostate cancer.

### Claim 41 (depends on 40)

Method according to claim 40, wherein the lung cancer is preferably non-small cell lung cancer (NSCLC).

### Claim 42 (depends on 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41)

Method according to claims 22 to 41, wherein the sample of the patient comprises peripheral blood mono-nuclear cells (PBMCs).

### Claim 43 (depends on 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

Method according to claims 22 to 42, wherein in step (b) a hierarchical clustering algorithm is applied.

### Claim 44

Kit, diagnostic composition or device for the analysis of at least one marker gene set out in table 11 comprising at least one primer and/or probe selective for determining the expression level of at least one marker gene set out in table 11.

### Claim 45 (depends on 44)

Kit, diagnostic composition or device of claim 44, further comprising an enzyme for primer elongation, nucleotides and/or labeling agents.

### Claim 46

Microarray, comprising at least one probe selective for determining the expression level of at least one marker gene set out in table 11.

### Claim 47 (depends on 46)

Use of a microarray according to claim 46 for determining the prognosis of a cancer patient.

### Claim 48 (depends on 44, 45)

Use of a kit, diagnostic composition or device according to claim 44 or 45 for determining the prognosis of a cancer patient.

### Claim 49

A method of determining the prognosis of a patient comprising the steps of
(a) determining the expression level of at least one marker gene selected from the group consisting of the marker genes set out in table 6 in a sample of the patient to obtain a gene expression profile;
(b) determining the prognosis of the patient based on the gene expression profile obtained in step (a).

### Claim 50 (depends on 49)

Method according to claim 49, wherein the patient is a cancer or tumor patient.

### Claim 51 (depends on 49, 50)

Method according to claim 49 or 50, wherein the at least one marker genes is selected from the group consisting of marker genes set out in table 7.

### Claim 52 (depends on 51)

Method according to claim 51, wherein the at least one marker gene is selected from the group consisting of marker genes set out in table 8.

### Claim 53 (depends on 51)

Method according to claim 51, wherein the at least one marker gene is selected from group consisting of marker genes set out in table 9.

### Claim 54 (depends on 51)

Method according to claim 51, wherein the at least one marker gene is selected from group consisting of marker genes set out in table 10.

### Claim 55 (depends on 49)

Method according to claim 49, wherein at least 10 marker genes, preferably at least 30 marker genes, more preferably at least 50 marker genes, most preferably at least 100 marker genes are selected from table 6.

### Claim 56 (depends on 51)

Method according to claim 51, wherein at least 10 marker genes, preferably at least 30 marker genes, more preferably at least 50 marker genes, most preferably at least 100 marker genes are selected from table 7.

### Claim 57 (depends on 52)

Method according to claim 52, wherein at least 10 marker genes, preferably at least 30 marker genes, more preferably at least 50 marker genes are selected from table 8.

### Claim 58 (depends on 53)

Method according claim 53, wherein at least 10 marker genes, preferably at least 20 marker genes, more preferably at least 30 marker genes a selected from the group consisting of from table 9.

### Claim 59 (depends on 49, 50, 51, 52, 53, 54, 55, 56, 57, 58)

Method according to any one of claims 49 to 58, wherein the expression level of at least one marker gene is measured before administration and/or after administration of at least one dose of a therapeutic agent.

### Claim 60 (depends on 59)

Method according to claim 59, wherein the gene expression profile of step (a) is obtained by determining the difference of the expression level of the at least one marker gene measured before administration of the therapeutic agent and after administration of at least one dose of the therapeutic agent.

### Claim 61 (depends on 59, 60)

Method according to claim 59 or 60, wherein the therapeutic agent is an immunostimulatory composition and/or a vaccine and/or an immunotherapeutic agent.

### Claim 62 (depends on 59, 60, 61)

Method according to any one of claims 59 to 61, wherein the immunostimulatory composition and/or vaccine comprises at least one antigen selected from the group consisting of PSA, PSMA, PSCA, STEAP, PAP and MUC1 or fragments or variants thereof.

### Claim 63 (depends on 59, 60, 61, 62)

Method according to any one of claims 59 to 62, wherein the immunostimulatory composition and/or vaccine comprises the antigens PSA, PSMA, PSCA, STEAP, PAP and MUC1 or fragments or variants thereof.

### Claim 64 (depends on 62, 63)

Method according to claim 62 or 63, wherein the antigen(s) are present as peptides or proteins and/or are encoded by at least one nucleotide sequence.

### Claim 65 (depends on 59, 60, 61, 62, 63, 64)

Method according to any one of claims 59 to 64, wherein the antigen(s) are encoded by at least one mRNA molecule.

### Claim 66 (depends on 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65)

Method according to any one of claims 50 to 65, wherein the cancer is selected from the group consisting of Acute Lymphoblastic Leukemia, Adult; Acute Lymphoblastic Leukemia, Childhood; Acute Myeloid Leukemia, Adult; Adrenocortical Carcinoma; Adrenocortical Carcinoma, Childhood; AIDS-Related Lymphoma; AIDS-Related Malignancies; Anal Cancer; Astrocytoma, Childhood Cerebellar; Astrocytoma, Childhood Cerebral; Bile Duct Cancer, Extrahepatic; Bladder Cancer; Bladder Cancer, Childhood; Bone Cancer, Osteosarcoma/Malignant Fibrous Histiocytoma; Brain Stem Glioma, Childhood; Brain Tumor, Adult; Brain Tumor, Brain Stem Glioma, Childhood; Brain Tumor, Cerebellar Astrocytoma, Childhood; Brain Tumor, Cerebral Astrocytoma/Malignant Glioma, Childhood; Brain Tumor, Ependymoma, Childhood; Brain Tumor, Medulloblastoma, Childhood; Brain Tumor, Supratentorial Primitive Neuroectodermal Tumors, Childhood; Brain Tumor, Visual Pathway and Hypothalamic Glioma, Childhood; Brain Tumor, Childhood (Other); Breast Cancer; Breast Cancer and Pregnancy; Breast Cancer, Childhood; Breast Cancer, Male; Bronchial Adenomas/Carcinoids, Childhood: Carcinoid Tumor, Childhood; Carcinoid Tumor, Gastrointestinal; Carcinoma, Adrenocortical; Carcinoma, Islet Cell; Carcinoma of Unknown Primary; Central Nervous System Lymphoma, Primary; Cerebellar Astrocytoma, Childhood; Cerebral Astrocytoma/Malignant Glioma, Childhood; Cervical Cancer; Childhood Cancers; Chronic Lymphocytic Leukemia; Chronic Myelogenous Leukemia; Chronic Myeloproliferative Disorders; Clear Cell Sarcoma of Tendon Sheaths; Colon Cancer; Colorectal Cancer, Childhood; Cutaneous T-Cell Lymphoma; Endometrial Cancer; Ependymoma, Childhood; Epithelial Cancer, Ovarian; Esophageal Cancer; Esophageal Cancer, Childhood; Ewing's Family of Tumors; Extracranial Germ Cell Tumor, Childhood; Extragonadal Germ Cell Tumor; Extrahepatic Bile Duct Cancer; Eye Cancer, Intraocular Melanoma; Eye Cancer, Retinoblastoma; Gallbladder Cancer; Gastric (Stomach) Cancer; Gastric (Stomach) Cancer, Childhood; Gastrointestinal Carcinoid Tumor; Germ Cell Tumor, Extracranial, Childhood; Germ Cell Tumor, Extragonadal; Germ Cell Tumor, Ovarian; Gestational Trophoblastic Tumor; Glioma. Childhood Brain Stem; Glioma. Childhood Visual Pathway and Hypothalamic; Hairy Cell Leukemia; Head and Neck Cancer; Hepatocellular (Liver) Cancer, Adult (Primary); Hepatocellular (Liver) Cancer, Childhood (Primary); Hodgkin's Lymphoma, Adult; Hodgkin's Lymphoma, Childhood; Hodgkin's Lymphoma During Pregnancy; Hypopharyngeal Cancer; Hypothalamic and Visual Pathway Glioma, Childhood; Intraocular Melanoma; Islet Cell Carcinoma (Endocrine Pancreas); Kaposi's Sarcoma; Kidney Cancer; Laryngeal Cancer; Laryngeal Cancer, Childhood; Leukemia, Acute Lymphoblastic, Adult; Leukemia, Acute Lymphoblastic, Childhood; Leukemia, Acute Myeloid, Adult; Leukemia, Acute Myeloid, Childhood; Leukemia, Chronic Lymphocytic; Leukemia, Chronic Myelogenous; Leukemia, Hairy Cell; Lip and Oral Cavity Cancer; Liver Cancer, Adult (Primary); Liver Cancer, Childhood (Primary); Lung Cancer, Non-Small Cell; Lung Cancer, Small Cell; Lymphoblastic Leukemia, Adult Acute; Lymphoblastic Leukemia, Childhood Acute; Lymphocytic Leukemia, Chronic; Lymphoma, AIDS-Related; Lymphoma, Central Nervous System (Primary); Lymphoma, Cutaneous T-Cell; Lymphoma, Hodgkin's, Adult; Lymphoma, Hodgkin's; Childhood; Lymphoma, Hodgkin's During Pregnancy; Lymphoma, Non-Hodgkin's, Adult; Lymphoma, Non-Hodgkin's, Childhood; Lymphoma, Non-Hodgkin's During Pregnancy; Lymphoma, Primary Central Nervous System; Macroglobulinemia, Waldenstrom's; Male Breast Cancer; Malignant Mesothelioma, Adult; Malignant Mesothelioma, Childhood; Malignant Thymoma; Medulloblastoma, Childhood; Melanoma; Melanoma, Intraocular; Merkel Cell Carcinoma; Mesothelioma, Malignant; Metastatic Squamous Neck Cancer with Occult Primary; Multiple Endocrine Neoplasia Syndrome, Childhood; Multiple Myeloma/Plasma Cell Neoplasm; Mycosis Fungoides; Myelodysplasia Syndromes; Myelogenous Leukemia, Chronic; Myeloid Leukemia, Childhood Acute; Myeloma, Multiple; Myeloproliferative Disorders, Chronic; Nasal Cavity and Paranasal Sinus Cancer; Nasopharyngeal Cancer; Nasopharyngeal Cancer, Childhood; Neuroblastoma; Neurofibroma; Non-Hodgkin's Lymphoma, Adult; Non-Hodgkin's Lymphoma, Childhood; Non-Hodgkin's Lymphoma During Pregnancy; Non-Small Cell Lung Cancer; Oral Cancer, Childhood; Oral Cavity and Lip Cancer; Oropharyngeal Cancer; Osteosarcoma/Malignant Fibrous Histiocytoma of Bone; Ovarian Cancer, Childhood; Ovarian Epithelial Cancer; Ovarian Germ Cell Tumor; Ovarian Low Malignant Potential Tumor; Pancreatic Cancer; Pancreatic Cancer, Childhood’, Pancreatic Cancer, Islet Cell; Paranasal Sinus and Nasal Cavity Cancer; Parathyroid Cancer; Penile Cancer; Pheochromocytoma; Pineal and Supratentorial Primitive Neuroectodermal Tumors, Childhood; Pituitary Tumor; Plasma Cell Neoplasm/Multiple Myeloma; Pleuropulmonary Blastoma; Pregnancy and Breast Cancer; Pregnancy and Hodgkin's Lymphoma; Pregnancy and Non-Hodgkin's Lymphoma; Primary Central Nervous System Lymphoma; Primary Liver Cancer, Adult; Primary Liver Cancer, Childhood; Prostate Cancer; Rectal Cancer; Renal Cell (Kidney) Cancer; Renal Cell Cancer, Childhood; Renal Pelvis and Ureter, Transitional Cell Cancer; Retinoblastoma; Rhabdomyosarcoma, Childhood; Salivary Gland Cancer; Salivary Gland’ Cancer, Childhood; Sarcoma, Ewing's Family of Tumors; Sarcoma, Kaposi's; Sarcoma (Osteosarcoma)/Malignant Fibrous Histiocytoma of Bone; Sarcoma, Rhabdomyosarcoma, Childhood; Sarcoma, Soft Tissue, Adult; Sarcoma, Soft Tissue, Childhood; Sezary Syndrome; Skin Cancer; Skin Cancer, Childhood; Skin Cancer (Melanoma); Skin Carcinoma, Merkel Cell; Small Cell Lung Cancer; Small Intestine Cancer; Soft Tissue Sarcoma, Adult; Soft Tissue Sarcoma, Childhood; Squamous Neck Cancer with Occult Primary, Metastatic; Stomach (Gastric) Cancer; Stomach (Gastric) Cancer, Childhood; Supratentorial Primitive Neuroectodermal Tumors, Childhood; T-Cell Lymphoma, Cutaneous; Testicular Cancer; Thymoma, Childhood; Thymoma, Malignant; Thyroid Cancer; Thyroid Cancer, Childhood; Transitional Cell Cancer of the Renal Pelvis and Ureter; Trophoblastic Tumor, Gestational; Unknown Primary Site, Cancer of, Childhood; Unusual Cancers of Childhood; Ureter and Renal Pelvis, Transitional Cell Cancer; Urethral Cancer; Uterine Sarcoma; Vaginal Cancer; Visual Pathway and Hypothalamic Glioma, Childhood; Vulvar Cancer; Waldenstrom's Macro globulinemia; and Wilms' Tumor.

### Claim 67 (depends on 66)

Method according to claim 66, wherein the cancer is prostate cancer.

### Claim 68 (depends on 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67)

Method according to any one of claims 49 to 67, wherein the sample of the patient comprises peripheral blood mono-nuclear cells (PBMCs).

### Claim 69 (depends on 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68)

Method according to any one of claims 49 to 68, wherein in step (b) a hierarchical clustering algorithm is applied.

### Claim 70

Kit, diagnostic composition or device for the analysis of at least one marker gene set out in table 6 comprising at least one primer and/or probe selective for determining the expression level of at least one marker gene set out in table 6.

### Claim 71 (depends on 70)

Kit, diagnostic composition or device of claim 70, further comprising an enzyme for primer elongation, nucleotides and/or labeling agents.

### Claim 72

Microarray, comprising at least one probe selective for determining the expression level of at least one marker gene set out in table 6.

### Claim 73 (depends on 72)

Use of a microarray according to claim 72 for determining the prognosis of a cancer patient.

### Claim 74 (depends on 70, 71)

Use of a kit, diagnostic composition or device according to claim 70 or 71 for determining the prognosis of a cancer patient.
